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HMGA2 is a non-histone chromosomal high-mobility group A
(HMGA) family protein that binds to the minor groove of
AT-rich DNA sequences (Fusco and Fedele, 2007; Grosschedl
et al., 1994). The HMGA2 protein does not have direct
transcriptional activity but rather transforms the chromatin
structure through its DNA binding (Thanos and Maniatis,
1992); these changes in chromatin architecture can alter
the local transcription. In general, HMGA2 is highly
expressed during embryogenesis and is nearly undetectable
in adult tissues (Chiappetta et al., 1996). In many cases,
HMGA2 is up-regulated in tumor cells in adult tissues
(Fedele et al., 2010; Young and Narita, 2007);
overexpression studies have generally shown that HMGA2
induces oncogenesis (Fedele et al., 2010). However, there
are some exceptions, particularly in adult stem cells.
Recent studies have proposed the possibility that HMGA2 is
intimately involved in the regulation of adult stem cells.
HMGA2 was highly expressed in neural stem cells (NSCs) and
regulated the stemness of NSCs in young mice (Nishino et
al., 2008). In humans, normal CD34-positive hematopoietic
stem cells (HSCs) express HMGA2, and the proliferation and
differentiation of HSCs are governed by HMGA2 (Rommel et
al., 1997). These data suggest that HMGA2 may have critical
roles in regulating stemness in NSCs or HSCs and also in
hUCBSCs. Our previous study showed that the expression of
HMGA2, p16INK4A, p21CIP1/WAF1 and p27KIP1 was strongly
affected by the aging of hUCBSCs (Lee et al., 2011). These
results indicate that HMGA2 has crucial roles in adult stem
cells, especially hUCBSCs, and can regulate stem cell aging
in addition to proliferation and differentiation.
Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases
that are involved in the control of stem cell proliferation
(Welham et al., 2011). Previously, we reported that the
PI3K signaling pathway determines the proliferation and
differentiation potential of hUCBSCs (Yu et al., 2012).
PI3K is one component of an intracellular signaling
cascade that also involves AKT and mammalian target of
rapamycin (mTOR). The PI3K/AKT/mTOR pathway regu-
lates several cellular functions, such as proliferation,
growth, survival, mobility and tumorigenesis, and several
studies have investigated the PI3K/AKT/mTOR pathway
within the context of adult stem cell regulation
(Mantovani et al., 1998; Martelli et al., 2011). However,
the interactions between PI3K/AKT/mTOR and HMGA2 in
adult stem cells remain uncharacterized.
p16Ink4a and p19Arf, also known as cyclin-dependent
kinase inhibitors, are well-known tumor suppressor genes.
There is considerable evidence that p16Ink4a and p19Arf
promote cellular aging (Bennecke et al., 2010; Collado et
al., 2007), and previous studies have shown that HMGA2
modulates stemness and aging by reducing p16Ink4a and
p19Arf expression in adult stem cells (Nishino et al., 2008).
However, it remains unknown whether HMGA2 regulates
p16Ink4a and p19Arf directly or indirectly in adult stem cells.
In this study, we elucidate the mechanistic relationship
among p16Ink4a, p19Arf and HMGA2 within the context of the
PI3K/AKT/mTOR/p70S6K pathway. Moreover, our results
confirm that HMGA2 regulates the proliferation and aging
of hUCBSCs.Materials and methods
Cell culture
hUCBSCs were isolated and cultured as previously described
(Park et al., 2012). Briefly, hUCBSCs were obtained from
umbilical cord blood immediately after the full-term
delivery of newborns from 20- to 30-year-old mothers;
each mother provided written informed consent for the
procedure. The blood samples were processed within 24 h of
collection. The UCB samples were mixed with HetaSep
solution (Stem Cell Technology, Vancouver, Canada) at a
ratio of 5:1 (v/v) and were then incubated at room
temperature until the red blood cells were depleted. The
supernatant was collected and centrifuged through a Ficoll
density-gradient at 600 ×g for 20 min. Mononuclear cells
were harvested and seeded on culture dishes under normal
culture conditions. The hUCBSCs were maintained in
endothelial cell growth medium-2 (EGM-2, Lonza, Basel,
Switzerland) containing 10% fetal bovine serum (FBS). The
isolation and research protocols were approved by the
Boramae Hospital Institutional Review Board (IRB). All of
the procedures were approved by the IRB of Seoul National
University (hUCBSC, #0603/001-002).Transfection
To overexpress the HMGA2 protein, the coding sequence of
full-length human HMGA2 was cloned into the pMX
retroviral vector. Viral production and transduction were
performed as previously described (Yu et al., 2012).
Briefly, the HMGA2 plasmid was transfected into 293 T
cells along with the VSV-G and gag/pol plasmids. The viral
supernatants were collected at 48 and 72 h
post-transfection and used to infect human hUCBSCs in
the presence of 5 μg/mL polybrene (Sigma-Aldrich, Sigma,
Ronkonkoma, NY, USA).Microarray
Total RNA was purified and amplified using the Ambion
Illumina RNA amplification kit (Ambion, Austin, TX),
according to the manufacturer's instructions, to yield
biotinylated cRNA. Briefly, 550 ng of total RNA was
reverse-transcribed to cDNA using a T7 oligo(dT) primer.
Second-strand cDNA was synthesized, in vitro transcribed,
and labeled with biotin-NTP. After purification, the cRNA
was quantified using the ND-1000 Spectrophotometer
(NanoDrop, Wilmington, NC), and 750 ng of labeled cRNA
was hybridized to each humanHT-12 expression v.4 bead
array for 16–18 h at 58 °C, as indicated by the manufacturer
(Illumina, Inc., San Diego, CA). The array signal was
detected using Amersham FluoroLink Cy3-streptavidin (GE
Healthcare Bio-Sciences, Little Chalfont, UK) following the
protocol described in the bead array manual. The arrays
were scanned using an Illumina Bead Array Reader confocal
scanner. The array data export processing and analysis was
performed using Illumina Bead Studio v3.1.3 (Gene Expres-
sion Module v3.3.8).
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159HMGA2 regulates in vitro aging through mTOR signalingImmunocytochemistry
The cells were fixed in 4% paraformaldehyde for 10 min at
room temperature. The cells were then permeabilized by
exposure to 0.5% Triton X-100 for 10 min at room temper-
ature and then blocked for 2 h with 10% normal goat serum
(Zymed, San Francisco, CA) at room temperature. The primary
antibodies were used at the manufacturer's recommended
dilution in 5% normal goat serum. Rabbit anti-HMGA2 (ab41878,
Abcam, Cambridge, MA) was used for the immunostaining.
The secondary antibody, goat anti-rabbit Alexa Fluor 594
(Invitrogen, Carlsbad, CA), was used at a 1:1000 dilution. The
nuclei were counterstained with 4′,6-diamidino-2-phenylindole
(DAPI; Sigma-Aldrich).Reverse transcription polymerase chain reaction
(RT-PCR) and real-time PCR
Total RNA was isolated from cells using the TRIzol reagent
following the protocol provided by the manufacturer
(Invitrogen) and used for cDNA synthesis using the Super-
script III First-Strand Synthesis System (Invitrogen). For
RT-PCR, the cDNA and primers were combined with a PCR
premix (Bioneer, Sung Nam, Rep. of Korea) and analyzed by
gel electrophoresis on 1.5% agarose gels with ethidium
bromide staining, followed by fluorescence digitization using
a Bio-Rad GelDoc XR system (Bio-Rad). Real-time PCR was
performed by mixing cDNA with each primer and the SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA).
According to the manufacturer's instructions, an ABI 7300
sequence detection system with supplied software (Applied
Biosystems) was used to quantify gene expression. Each gene
was normalized with β-actin as a housekeeping control. At
least three independent analyses were done for each gene.
The primer sets used for this study are listed in Supplemen-
tary Table 1.Western blotting
Whole-cell protein lysates were extracted in a solution
containing 1% Triton X-100, 20 mM Tris HCl (pH 8), 137 mM
NaCl, 10% glycerol and 2 mM EDTA (Sigma-Aldrich). Nuclear
and cytoplasmic lysates were extracted using NE-PER reagents
(Thermo, Rockford, IL), and the protein concentrations were
determined using a DC assay kit (Bio-Rad, Hercules, CA). The
proteins were separated by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred
to nitrocellulose membranes at 100 V and 350 mA for 2 h, and
probed with primary antibodies. The secondary antibodies
were used according to the manufacturer's specifications, andFigure 1 HMGA2 overexpression enhances cell proliferation and
determined using a GFP virus. Scale bar=10 μm. (B) Immunocytoche
virus- or HMGA2 virus-infected cells. Nuclei were stained using DAPI (
early-stage hUCBSCs after transformation with the GFP control or HM
was analyzed during repeated subculture-induced senescence of hUC
control and HMGA2-overexpressing early- and late-stage hUCBSCs.
hUCBSCs after transformation with the GFP control or HMGA2 ove
performed in the GFP control and HMGA2-overexpressing early- and l
in the GFP control and HMGA2-overexpressing late-stage hUCBSCs tobinding was detected using an enhanced chemiluminescence
(ECL) detection kit (Amersham, Piscataway, NJ) according
to the manufacturer's instructions.
siRNA inhibition study
Transient transfection assays were performed using specific,
commercially available siRNA targeting HMGA2 (Dharmacon, ON
Target plus SMART pool, Cat #L-013495-00-0005, Lafayette, CO,
USA) along with a non-targeting siRNA (Dharmacon, ON Target
plus SMART pool, Cat #D-001810-01). The siRNA trans-
fections were performed according to the manufacturer's
instructions. Briefly, the cells were seeded at a concentra-
tion of 5×104/well, and siRNA-containing media (without
added antibiotics) were added when the cells reached 50-60%
confluence. The cells were incubated with 50 nM siRNA
for 48 h. The cells were subcultured 48–72 h following the
siRNA transfection to evaluate mRNA expression and protein
expression. After these incubations, RNA and protein extrac-
tions were performed for genetic and proteomic analyses.
Senescence-associated beta-galactosidase
(SA-β-gal) staining
SA β-gal staining was performed as previously described (So et
al., 2011). Briefly, the hUCBSCs were seeded in 6-well plates
at a density of 1×105/well for late-stage cells and 5×104/well
for early-stage cells. The cells were incubated for 3 days until
they reached the appropriate confluence and were then
washed twice with PBS and fixed with 0.5% glutaraldehyde in
PBS (pH 7.2) for 5 min at room temperature. The cells were
then washed with PBS containing 1 mM MgCl2 (pH 7.2) and
stained with X-gal solution (1 mg/ml X-gal, 0.12 mM K3Fe[CN]
6 (potassium ferricyanide), 0.12 mM K4Fe[CN]6 (potassium
ferrocyanide) and 1 mM MgCl2 in PBS, pH 6.0) overnight at
37 °C.
Flow cytometry
hUCBSCs were triturated into single cells and labeled with
monoclonal mouse anti-human fluorochrome-conjugated anti-
bodies (CD34-FITC, CD45-FITC, CD73-PE and CD105-FITC, all
from BD Bioscience, San Jose, CA). The labeled cells were
analyzed on a fluorescence-activated cell sorter, FACSAria
(BD Biosciences), using FACSDiva software (BD Biosciences).
MTT assay
The proliferation potential was measured using the MTT assay,
which is based on the ability of live cells to convert tetrazoliumreduces β-gal activity. (A) Viral transduction efficiency was
mical analyses of HMGA2 were performed using both the control
blue). Scale bar=100 μm or 10 μm. (C) Heat map of the mRNAs in
GA2 overexpression viruses. (D) The expression level of HMGA2
BSCs, as shown by RT-PCR (E) Phase contrast images of the GFP
Scale bar=100 μm. (F) Heat map of the mRNAs in late-stage
rexpression viruses. (G) The MTT cell proliferation assay was
ate-stage hUCBSCs. (**Pb0.01) (H) β-gal staining was performed
confirm their senescence.
160 K.-R. Yu et al.salt into purple formazan. Briefly, the cells (1×104 cells per
well) were seeded in 24-well microplates in 450 μl of medium.
After 48 h, 50 μl of MTT stock solution (5 mg/ml, Sigma-
Aldrich) was added to each well, and the plates were further
incubated for 4 h at 37 °C. The supernatant was removed, and
200 μl DMSO was added to each well to solubilize the purple
formazan crystals. The absorbance at a wavelength of 540 nm
was measured using an EL800 microplate reader (BIO-TEK In-
struments, Winooski, VT).
In vitro differentiation assay
In vitro differentiation into the adipogenic and osteogenic
lineages was performed as described previously (Yu et
al., 2012). Briefly, hUCBSCs (1×105) were plated in six-well
plates. After the cells had attained 70%-80% confluence,
they were treated with an adipogenic induction medium
(DMEM supplemented with 5% FBS, 1 μM dexamethasone,
10 μM insulin, 200 μM indomethacin and 0.5 mM
isobutylmethylxanthine) or an osteogenic induction medium
(DMEM supplemented with 10% FBS and 200 μM indomethacin,
1 μM dexamethasone, 0.5 mM isobutyl methylxanthine and
0.5 μg/mL insulin). DMEM supplemented with 10% FBS was
used as a control. Media were changed twice weekly. After
two weeks of induction, the cells were stained to confirm
adipogenic or osteogenic differentiation. Intracellular lipid
accumulation, an indicator of adipogenic differentiation, was
visualized by Oil Red O staining. Osteogenic differentiation
was noted by positive staining with Alizarin Red stain, which
is specific for calcium.
For chondrogenic differentiation, 5×105 cells were added
to a 15-mL polypropylene tube and incubated with 1 mL
of chondrocyte differentiation medium (Lonza, Wakersville,
MD, USA) for three weeks. The round pellets were embedded
in paraffin and cut into 3-μm sections. The sections were
stained with toluidine blue.
Inhibitor studies
To assess the effect of PI3K/AKT signaling on HMGA2 over-
expression, an inhibition study was conducted. HMGA2-
overexpressing hUCBSCs were treated with 30 μM of
LY294002 (Calbiochem, La Jolla, CA) for inhibition of the
PI3K signaling pathway (Yu et al., 2012).
Statistical analyses
The data were analyzed using Student's t-test in Excel
software. The results are expressed as the mean±the standard
error, and statistically significant data are indicated with
asterisks (**Pb0.01).
Results
Characterization of hUCBSCs
To determine the multilineage differentiation potential of
hUCBSCs, we induced the in vitro differentiation of the
adipogenic, osteogenic and chondrogenic lineages. The condi-
tion medium-induced hUCBSCs were positive for Oil Red O,Alizarin Red S and Toluidine Blue staining (Figs. 3E, S1A, B).
The hUCBSCswere positive for the hUCBSCsmarkers (CD73 and
CD105) but negative for the hematopoietic cell and leukocyte
markers (CD34 and CD45; Fig. S1C).
HMGA2 target identification using microarray
analyses
To demonstrate the role of HMGA2 in regulating proliferation
and senescence, early-stage (fewer than 8 passages)
hUCBSCs were transduced with control GFP or HMGA2
virus. We observed that the transduction efficiency was
higher than 80%, which was sufficient to overexpress the
target gene (Fig. 1A). The elevation of the HMGA2
expression level in the HMGA2-overexpressing hUCBSCs was
confirmed by immunocytochemical analyses (Fig. 1B). To
investigate the role of HMGA2 in hUCBSCs, we compared the
gene expression pattern in HMGA2-overexpressing and
-non-overexpressing cells using microarray analyses. A GFP
expression vector was used as the control. These results
showed that HMGA2 overexpression produces distinct gene
expression patterns in early-stage hUCBSCs (Fig. 1C). The list
of the detected genes and their fold changes between the
HMGA2-overexpressing and -non-overexpressing cells are
given in Supplementary Table 2.
HMGA2 enhances hUCBSCs proliferation and reduces
β-gal activity
hUCBSCs showed gradually decreased expression of HMGA2
following consecutive passages (Fig. 1D). Late-stage (more
than 16 passages) hUCBSCs were followed the induction of
replicative senescence by repeated subculture. The late-stage
hUCBSCs showed flattened or lengthened morphology, which
is considered a phenotype of senescent cells. However, the
overexpression of HMGA2 slightly reduced the senescent
morphology in the late-stage hUCBSCs (Fig. 1E). We also
compared the gene expression pattern in late-stage hUCBSCs
using microarray analyses. A GFP expression vector was used
as the control in the same manner. The results demonstrated
that HMGA2 overexpression causes also distinct gene expres-
sion patterns even in late-stage hUCBSCs (Fig. 1F). Next, we
assayed the proliferation by MTT and performed SA-β-gal
staining to confirm the senescent state of the hUCBSCs. The
late-stage hUCBSCs showed both elevated SA-β-gal activity
and decreased proliferation (Fig. S2E, Fig. 1G). However, the
overexpression of HMGA2 in these cells reduced the SA-β-gal
activity and enhanced the proliferation rate (Figs. 1G, H).
HMGA2 activates PI3K/AKT and its sequential
downstream effectors mTOR/p70S6K
To better characterize gene expression patterns, we used IPA
software and identified several canonical signaling pathways
and molecular/cellular functions that were related to HMGA2
overexpression (Figs. 2A, B). Both eIF4 and p70S6K signaling,
which are associated with translational regulation, were highly
ranked among the canonical signaling pathways activated
(Fig. 2A). Moreover, eIF4- and p70S6K-related signaling, such
as mTOR and PI3K/AKT signaling, were also highly ranked.
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Figure 2 HMGA2 overexpression activates the PI3K/AKT and
mTOR/p70S6K pathways. (A) Canonical signaling pathways
activated in HMGA2-overexpressing hUCBSCs, as determined
by IPA. (B) Molecular/cellular functions activated in HMGA2-
overexpressing hUCBSCs by IPA. (C) A Western blot analysis
was conducted using the GFP control, HMGA2-overexpressing,
HMGA2-overexpressing and LY294002-treated hUCBSCs. The
phosphorylation of AKT and its downstream effectors mTOR,
p70S6K, p21CIP1/WAF1 and p16INK4A were analyzed.
161HMGA2 regulates in vitro aging through mTOR signalingFunctional analysis showed that, overall, cellular growth- and
death-associated functions were highly ranked (Fig. 2B). To
determine the role of HMGA2 in regulating the PI3K/AKT
signaling pathway, a Western blot analysis was conducted in
the presence or absence of the PI3K inhibitor LY294002
(Fig. 2C). The phosphorylation of AKT, mTOR and p70S6K were
induced by HMGA2 and inhibited by the treatment with
LY294002, whereas the expression of total proteins was
unaffected. However, the expression levels of the cyclin-
dependent kinase inhibitors p16INK4A and p21CIP1/WAF1 were
inhibited by HMGA2 overexpression. The treatment of LY294002
restores protein levels of p16INK4A and p21CIP1/WAF1 to baseline
level, suggesting that the PI3K/AKT/mTOR/p70S6K pathway is
sufficient for reducing the p16INK4A and p21CIP1/WAF1 expression.
These results suggest that HMGA2 activation was associated
with the activation of the PI3K/AKT/mTOR/p70S6K signaling
pathway and the inhibition of p16INK4A and p21CIP1/WAF1
expression.
HMGA2 inhibition down-regulates cell proliferation
and adipogenic differentiation potential
To elucidate the precise role of HMGA2 in early-stage
hUCBSCs, we conducted inhibition studies using siRNA.
Further microarray analyses showed that the HMGA2-inhibited
early-stage hUCBSCs, siHMGA2 transfected cells, have different
gene expression patterns than the control siRNA-treated cells
(Fig. 3A). Following the inhibition of HMGA2 by transfection of
siRNA, we assayed proliferation by MTT and performed SA-β-gal
staining to confirm the senescent state of the hUCBSCs. The
siHMGA2 transfected hUCBSCs showed elevated SA-β-gal
activity and a decrease in proliferation (Figs. 3B, C). We next
performed western blot analysis to determine whether the
PI3K/AKT/mTOR pathway was involved in HMGA2 expression.
As shown in Fig. 3D, phospho-AKT (Ser473), phospho-mTOR
(Ser2448) and phospho-p70S6K (Thr421/Ser424) activities were
dramatically decreased, whereas p16INK4A and p21CIP1/WAF1
activities were increased in siHMGA2 transfected cells. To
compare the adipogenic differentiation capacity of the control
siRNA and siHMGA2 transfected cells, we induced the in vitro
differentiation of both populations into the adipogenic lineage.
After adipogenic induction, the HMGA2 down-regulated hUC
BSCs showed a reduced adipogenic differentiation potential
when compared to the control siRNA-treated hUCBSCs, as
evidenced by Oil Red O staining (Fig. 3E). The gene expression
levels of adipogenic transcription factors, including PPARγ, aP2
and C/EBP-β, were significantly decreased in the siHMGA2
transfected cells compared to the control siRNA transfected
cells (Figs. 3F–H). Taken together, these data suggest that the
down-regulation of HMGA2 compromised cell proliferation and
adipogenic differentiation via regulation of the PI3K/AKT/
mTOR pathway.
HMGA2 regulates cell cycle-related genes and other
genes
There were several genes that exhibited directly opposite
patterns in the HMGA2-overexpressing and siHMGA2 hUCBSCs
(Figs. 1C, 3A, Supplementary Table 2). Among these genes,
we selected eight genes that were highly related to the
top-rated signaling pathways defined by the Ingenuity
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Figure 3 HMGA2 inhibition compromised cell proliferation and adipogenic differentiation. (A) Heat map of the mRNAs in the control
siRNA and siHMGA2-transfected hUCBSCs. (B) The MTT cell proliferation assaywas performed in the siHMGA2-treated cells and the control
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162 K.-R. Yu et al.Pathway Analysis (IPA) software (Figs. 4A, B). Three of these
genes, Cyclin F, Cyclin E1 and CDC25A, were up-regulated
when HMGA2 was overexpressed and down-regulated when
HMGA2 was inhibited. The other five genes, C14orf153,
EID2B, ZNF394, CDKN2AIPNL and C9orf80, showed the
opposite expression pattern. We performed RT-PCR to
quantify the actual expression of the selected genes. We
found that cell cycle-related genes, such as cyclin F, cyclin
E1 and CDC25A, were up-regulated after HMGA2
overexpression. In contrast, EID2B, CDKN2A IPNL, C9orf80,
C14orf153 and ZNF394 were down-regulated after HMGA2
overexpression. Cyclin-dependent kinase inhibitors, such as
p16INK4A, p19ARF and p21CIP1/WAF1, were up-regulated in the
late-stage cells compared to the early-stage cells. However,
the overexpression of HMGA2 led to a significant reduction of
p16INK4A, p19ARF and p21CIP1/WAF1 expression in both the early-
and late-stage hUCBSCs (Fig. 4C).DiscussionThe DNA-binding protein HMGA2 is abundantly expressed in
embryonic stem cells and during embryogenesis (Chiappetta
et al., 1996; Li et al., 2006). Furthermore, HMGA2 was highly
expressed in fetal and young adult stem cells, such as
hematopoietic stem cells or neural stem cells, and its
expression was decreased upon aging. However, the role
of HMGA2 in adult stem cells has not been fully elucidated.
To investigate the role of HMGA2, we up-regulated and
down-regulated HMGA2 expression in hUCBSCs and analyzed
the subsequent gene expression pattern by microarray
assays. Because HMGA2 proteins act as both activators and
repressors of gene expression by altering chromatin struc-
ture, the expression of many genes was altered by HMGA2
expression. Among the biological functions revealed by IPA
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Figure 4 HMGA2 overexpression enhances the expression of Cyclin F, Cyclin E1 and CDC25A and reduces the cell cycle regulatory
genes p16, p19 and p21 in hUCBSCs. (A) Heat map of the genes that are differentially expressed between siHMGA2- and
HMGA2-overexpressing hUCBSCs. (B) Scatter plot of the genes that are differentially expressed between siHMGA2- and
HMGA2-overexpressing hUCBSCs. (C) The expression of genes that were found to be up- or down-regulated in the microarray
analyses were evaluated in the GFP control and HMGA2-overexpressing early- and late-stage hUCBSCs. (D) Schematic representation
of the HMGA2-induced signaling pathway.
163HMGA2 regulates in vitro aging through mTOR signalinganalysis, HMGA2 significantly affected factors involved in
gene expression, RNA post-transcriptional modification and
cellular growth and proliferation. We confirmed that cell
growth-related genes, such as Cyclin F, Cyclin E1 and
CDC25A, were up-regulated in the HMGA2-overexpressing
cells. Conversely, certain genes of unknown function, such as
CDKN2AIPNL, C9orf80, C14orf153, EID2B and ZNF394, were
down-regulated.
It has been reported that HMGA2 represses the transcrip-
tion of CDKN2A, p16INK4A and p19ARF in fetal and adult neural
stem cells (Nishino et al., 2008). HMGA2 contributes to adult
stem cell stemness by repressing the expression of p16INK4A
and p19ARF, but the expression of HMGA2 declines with age.
In agreement with this model, we confirmed that HMGA2
overexpression down-regulated cyclin-dependent kinase
inhibitors, such as p16INK4A and p19ARF. Furthermore, we
demonstrated that HMGA2 inhibited another cyclin-dependent
kinase inhibitor, p21CIP1/WAF1, in hUCBSCs. In our previous
study, we demonstrated the down-regulation of HMGA2 and
the up-regulation of p16INK4A in both replicative and HDAC
inhibitor-mediated senescence in hUCBSCs (Lee et al., 2011).
In the present study, we showed that the overexpression ofHMGA2 increased proliferation and decreased the SA-β-gal
activity in replicative senescent hUCBSCs (Fig. 1). Further-
more, we found that knockdown of HMGA2 in early-stage
hUCBSCs compromised cell proliferation and adipogenic
differentiation and led to enhanced SA-β-gal activity and
p16INK4A and p21CIP1/WAF1 expression. Our results indicated
that preventing the decline in HMGA2 expression during
the aging process may increase hUCBSC proliferation, in
part, by repressing cyclin-dependent kinase inhibitors.
To understand the molecular mechanisms by which
HMGA2 inhibits p16INK4A, p19ARF and p21CIP1/WAF1, it is
essential to identify the signaling pathways that are directly
regulated by HMGA2. To this end, we analyzed the gene
expression patterns in hUCBSC cell lines expressing GFP
(control), exogenous HMGA2 or siRNA against HMGA2. Micro-
array data sets were analyzed using IPA software. Among
the signaling pathways related to HMGA2 overexpression, we
confirmed that PI3K/AKT signaling is the major target
signaling pathway that is activated by HMGA2 activation
(Fig. 2A). A previous report also suggested that Hmga2
constitutively activates AKT in bone marrow cells from
ΔHmga2 mice, in which the 3′ untranslated region of Hmga2
164 K.-R. Yu et al.was removed (Ikeda et al., 2011). In ΔHmga2 mice, HMGA2-
mediated PI3K/AKT activation may play an important role in
controlling the proliferative hematopoiesis. However, the
molecular mechanism of HMGA2-mediated PI3K/AKT activa-
tion has yet to be elucidated. In normal cells, HMGA2 is mainly
confined to the nucleus (Fusco and Fedele, 2007; Grosschedl
et al., 1994), and therefore, HMGA2 exerts its effects by
regulating the expression of transcription factors (Mantovani
et al., 1998) and growth factors that are related to the PI3K/
AKT signaling pathway. Indeed, we found that IGFBP1
(insulin-like growth factor-binding protein), NGF (nerve
growth factor), EGFR (epidermal growth factor receptor),
HBEGF (heparin-binding EGF-like growth factor), ANGPTL4
(angiopoietin-related protein 4) and FGFRL1 (fibroblast
growth factor receptor-like 1) were up-regulated after
HMGA2 overexpression in hUCBSCs (Supplementary Table 2).
Indeed, we showed that the conditioned medium from
HMGA2-overexpressing hUCBSCs increased AKT phosphoryla-
tion in a paracrine manner (Fig. S2D). Therefore, it warrants
further studies to determine which factors regulate HMGA2-
mediated PI3K/AKT activation.
We demonstrated that the PI3K/AKT signaling pathway
plays important roles in regulating hUCBSC differentiation
and maintaining the pluripotency of hESCs (Yu et al., 2012).
Furthermore, mTOR/p70S6K, a major downstream effector
of PI3K/AKT signaling, was found to be phosphorylated,
suggesting that HMGA2 effectively activates the PI3K/AKT/
mTOR/p70S6K signaling pathway (Fig. 2C). It has been
reported that the up-regulation of the mTOR/p70S6K pathway
leads to increases in cyclin E and CDC25A activities (Chou
et al., 2003) and decreases the expression of p16INK4A (Gao et
al., 2004) and p21CIP1/WAF1 (Gao et al., 2003). To exclude
the possibility that the effect of HMGA2 on the PI3K/AKT
pathway is indirect, we demonstrated that the PI3K/AKT
phosphorylation was not changed in consecutive passages
(Fig. S2F).
We then performed experiments with the PI3K inhibitor,
LY294002 to confirm the control of the PI3K/AKT pathway by
HMGA2. Targets for LY294002 would be known downstream
targets for PI3K/AKT, which would include mTOR/p70S6K,
in the potential control of the expression of cyclin E,
CDC25A, p16INK4A and p21CIP1/WAF1. We found that the
LY294002 treatment was sufficient to reduce the activity
of the PI3K/AKT/mTOR/p70S6K pathway; this treatment
also further increased the number of SA-β-gal positive cells
and the expression of p16INK4A and p21CIP1/WAF1 (Figs. S2A–C).
However, the HMGA2 expression was not attenuated by
treatment with LY294002. These results suggest that HMGA2
regulates the PI3K/AKT/mTOR/p70S6K pathway. Further-
more, HMGA2-mediated down-regulation of p16INK4A and
p21CIP1/WAF1 expression was reversed by LY294002 treatment,
indicating that the HMGA2-PI3K/AKT/mTOR/p70S6K pathway
regulates gene expression rather than HMGA2 having a direct
influence on transcription.
Together, our data suggest the existence of a novel
signaling pathway that is induced by HMGA2 overexpression.
Given the previously reported interaction between histone
modification and miRNAs related to HMGA2 expression (Lee
et al., 2011), future studies should further evaluate the roles
of epigenetic regulatory mechanisms in HMGA2-regulated
signaling pathways. However, the data in this study clearly
demonstrate an important in vitro aging and proliferationregulatory role for HMGA2 in inducing PI3K/AKT/mTOR/
p70S6K signaling, resulting in the inhibition of p16INK4A and
p21CIP1/WAF1 expression in hUCBSCs.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2012.11.002.
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